| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diphtheria | D004165 | 2 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Dermatomycoses | D003881 | 17 associated lipids |
| Drug Eruptions | D003875 | 30 associated lipids |
| Dermatitis, Exfoliative | D003873 | 10 associated lipids |
| Cysts | D003560 | 4 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Cross Infection | D003428 | 9 associated lipids |
| Conjunctivitis, Bacterial | D003234 | 3 associated lipids |
| Conjunctival Neoplasms | D003230 | 3 associated lipids |
| Confusion | D003221 | 4 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Chromoblastomycosis | D002862 | 2 associated lipids |
| Chlamydia Infections | D002690 | 7 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Bronchitis | D001991 | 6 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Savarino V et al. | OAM for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930908 |
| Perri F et al. | Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421877 |
| Perri F et al. | Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421878 |
| Pilotto A et al. | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421879 |
| Tepes B et al. | Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421880 |
| Calvet X et al. | What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421884 |
| Huang J et al. | Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. | 2013 | Aliment. Pharmacol. Ther. | pmid:24117692 |
| Molina-Infante J et al. | Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. | 2010 | Aliment. Pharmacol. Ther. | pmid:20180787 |
| Chacko Y and Holtmann GJ | Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? | 2011 | Aliment. Pharmacol. Ther. | pmid:21679208 |
| Zullo A et al. | High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. | 2005 | Aliment. Pharmacol. Ther. | pmid:15948808 |
| Harb AH et al. | Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. | 2015 | Aliment. Pharmacol. Ther. | pmid:26011564 |
| Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12786632 |
| Gasbarrini A et al. | Efficacy of a multistep strategy for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632649 |
| Chan FK et al. | Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632651 |
| Pipkin GA et al. | Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768524 |
| Louw JA et al. | Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768531 |
| Laine L et al. | Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768532 |
| Tomita T et al. | Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966543 |
| Labenz J et al. | One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042978 |
| Labenz J et al. | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042979 |
| Di Caro S et al. | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876707 |
| Wu JC et al. | Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876709 |
| Basset C et al. | Helicobacter pylori infection: anything new should we know? | 2004 | Aliment. Pharmacol. Ther. | pmid:15335411 |
| Mason J et al. | The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876711 |
| Georgopoulos SD et al. | Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876712 |
| Savarino V et al. | Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:9892878 |
| Bazzoli F et al. | Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663723 |
| Pozzato P et al. | Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663724 |
| Goh KL et al. | Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? | 1997 | Aliment. Pharmacol. Ther. | pmid:9663838 |
| Goddard AF et al. | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233187 |
| Kolkman JJ et al. | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663840 |
| Miyaji H et al. | Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663841 |
| Wong BC et al. | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. | 2000 | Aliment. Pharmacol. Ther. | pmid:11069326 |
| Lionetti E et al. | Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:17032283 |
| Iijima K et al. | Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. | 2004 | Aliment. Pharmacol. Ther. | pmid:15153171 |
| Laurent J et al. | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11683693 |
| Sheu BS et al. | The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755841 |
| Gudjonsson H et al. | High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9845401 |
| Koivisto TT et al. | Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113368 |
| Cammarota G et al. | High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. | 2004 | Aliment. Pharmacol. Ther. | pmid:15043520 |
| Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
| Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
| Sheu BS et al. | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. | 2005 | Aliment. Pharmacol. Ther. | pmid:15691303 |
| Wong WM et al. | Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16423001 |
| Tsuzuki T et al. | Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966545 |
| Gisbert JP et al. | Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. | 2005 | Aliment. Pharmacol. Ther. | pmid:16268980 |
| Ellenrieder V et al. | Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9701524 |
| Miwa H et al. | Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? | 2003 | Aliment. Pharmacol. Ther. | pmid:12823158 |
| Lim AG et al. | Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. | 1997 | Aliment. Pharmacol. Ther. | pmid:9218079 |
| Zullo A et al. | Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? | 2010 | Aliment. Pharmacol. Ther. | pmid:20518756 |